A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery.
Michel Marty, MD
Centre for Therapeutic Innovations in Oncology and Haematology / Saint Louis University Hospital
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)